NCT05435742View on ClinicalTrials.gov

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

March 17, 2024

Study Completion Date

March 17, 2024

Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions
BIOLOGICAL

SON-080

Recombinant human interleukin-6 (rhIL-6)

Trial Locations (1)

3124

Emeritis Research, Camberwell

Sponsors
All Listed Sponsors
lead

Sonnet BioTherapeutics

INDUSTRY

NCT05435742 - SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) | Biotech Hunter | Biotech Hunter